Publications by authors named "Brian D Weiss"

Claim this Profile
T
The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma.
Chelsea Kotch, Alicia Gomes, Krista S Schatz, Eva Dombi, Symone Brown, Brian D Weiss

Hum Genet· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study.
Zahra Hudda, Aaron Webster, Eric Anderson, Priscila Badia, Rochelle Bagatell, Brian D Weiss

Transplant Cell Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell and Spatial Omics Reveals Region-Specific Plasticity and Therapeutic Vulnerabilities in Metastatic High-Risk Neuroblastoma.
Lai Man Natalie Wu, Janet L Oblinger, Dazhuan Xin, Rohit Rao, Feng Zhang, Brian D Weiss

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
Thomas Cash, Araz Marachelian, Steven G DuBois, Yueh-Yun Chi, Anahit Baregamyan, Brian D Weiss

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.
Eva Dombi, Andrea M Gross, Brigitte C Widemann, Brian D Weiss, Scott R Plotkin

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma.
Steven G DuBois, Chitose Ogawa, Lucas Moreno, Yaël P Mossé, Matthias Fischer, Brian D Weiss

Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma: A Children's Oncology Group Report.
Puja J Umaretiya, Arlene Naranjo, Fan F Zhang, Julie R Park, Brian D Weiss

JAMA Netw Open· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Dysfunction in Children and Young Adults Treated With MEK Inhibitors: A Retrospective, Single-Center Study.
Jonathan D Bender, Natasha Pillay-Smiley, Garick D Hill, Peter de Blank, Trent R Hummel, Brian D Weiss

JACC CardioOncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1.
Liny John, Gurbani Singh, Eva Dombi, Pamela L Wolters, Staci Martin, Brian D Weiss

Clin Trials· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Andras Heczey, Xin Xu, Amy N Courtney, Gengwen Tian, Gabriel A Barragan, Brian D Weiss

Nat Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gadolinium-based contrast media does not improve the staging of neuroblastoma image-defined risk factors at diagnosis.
Cara E Morin, Reem Hasweh, Chris Anton, Jonathan R Dillman, Emily Orscheln, Brian D Weiss

Pediatr Blood Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
Andrea M Gross, Eva Dombi, Pamela L Wolters, Andrea Baldwin, Anne Dufek, Brian D Weiss

Neuro Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Andras Heczey, Xin Xu, Amy N Courtney, Gengwen Tian, Gabriel A Barragan, Brian D Weiss

Nat Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.
Benjamin J Lerman, Yimei Li, Cecilia Carlowicz, Meaghan Granger, Thomas Cash, Brian D Weiss

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
Andrea M Gross, Brittany Glassberg, Pamela L Wolters, Eva Dombi, Andrea Baldwin, Brian D Weiss

Neuro Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of neurofibromatosis type 1-associated plexiform neurofibromas.
Michael J Fisher, Jaishri O Blakeley, Brian D Weiss, Eva Dombi, Shivani Ahlawat

Neuro Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
Peter M K de Blank, Andrea M Gross, Srivandana Akshintala, Jaishri O Blakeley, Gideon Bollag, Brian D Weiss

Neuro Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Ami V Desai, Giles W Robinson, Karen Gauvain, Ellen M Basu, Margaret E Macy, Brian D Weiss

Neuro Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining Violence Against Women at a Regional Level 1 Trauma Center During the COVID-19 Pandemic.
Brett M Tracy, Amy K Whitson, J C Chen, Brian D Weiss, Carrie A Sims

Am Surg· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A safety and feasibility trial of I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study.
Brian D Weiss, Gregory Yanik, Arlene Naranjo, Fan F Zhang, Wendy Fitzgerald

Pediatr Blood Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of pretreatment F-FDG positron emission tomography/computed tomography in pediatric neuroblastoma.
Andrew J Sung, Brian D Weiss, Susan E Sharp, Bin Zhang, Andrew T Trout

Pediatr Radiol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.
M Meaghan Granger, Arlene Naranjo, Rochelle Bagatell, Steven G DuBois, Jeannine S McCune, Brian D Weiss

Transplant Cell Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerance of dinutuximab therapy for treatment of high-risk neuroblastoma in two patients with end-stage renal disease on dialysis.
Myesa Emberesh, Jeremy D Rubinstein, Jennifer Young, Stefanie W Benoit, Christopher E Dandoy, Brian D Weiss

Pediatr Blood Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Brian D Weiss, Pamela L Wolters, Scott R Plotkin, Brigitte C Widemann, James H Tonsgard

J Clin Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sentinel lymph node biopsy in head and neck rhabdomyosarcoma.
Brian Turpin, Joseph G Pressey, Rajaram Nagarajan, Brian D Weiss, Andrew T Trout

Pediatr Blood Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis